Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07285291

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hyperphosphatemia Patients on Hemodialysis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Taisho Pharmaceutical Co., Ltd selected site

Tokyo, Japan

Location status: Recruiting

Location contact

Taisho Director Taisho Pharmaceutical Co., Ltd selected site

CONTACT

[email protected]

81-3-3985-1118

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to Visit 1 (Week -3)
  • Patients aged >=18 years at the time of obtaining informed consent
  • Patients with a serum phosphorus concentration of >= 5.5 mg/dL and < 10.0 mg/dL at Visit 1 (Week -3)
  • Patients who have been prescribed at least one phosphate binder within the approved dosage, and the prescribed drug and dosage regimen should have been unchanged during the last 2 weeks prior to Visit 1 (Week -3)

Exclusion criteria

  • Patients with confirmed serum intact PTH concentration > 500 pg/mL from Visit 1 (Week -3) to Visit 4 (Week 0)
  • Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)

Treatment and study plan

TS-172 20~60 mg/day

Drug

oral administration of TS-172 20~60 mg/day

Placebo

Drug

oral administration of placebo

Primary outcomes

  1. Achievement rate of the target serum phosphorus level

    Time frame: Week 8

Secondary outcomes

  1. Change from baseline in serum concentration of phosphorus

    Time frame: Up to Week 8

  2. Concentration of corrected serum calcium

    Time frame: Up to Week 8

  3. Serum Ca × P product

    Time frame: Up to Week 8

Study contacts

Contact information is provided by the study sponsor or research team.

Taisho Director Taisho Director

CONTACT

Taisho Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.

CONTACT

[email protected]

81-3-3985-1118

Sponsors and collaborators

Lead sponsor

Taisho Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 16, 2025
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.